Eli Lilly's GLP-1 Impact on ResMed Is Overblown: Barron's
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
GLP-1 Concerns Clobbered This Healthcare Stock. Now It's Time to Buy.
ResMed makes its bank from products that battle sleep apnea. When that business seemed threatened, investors fled. Now it looks like they were too hasty. By Jacob Sonenshine ResMed is the latest
Lilly Expecting Q2 IPR&D Pre-tax Charge of Around $0.14 per Share: Report
Executive Reshuffles: ChargePoint, Tupperware and ADM in Focus
In-Depth Analysis: Eli Lilly and Co Versus Competitors In Pharmaceuticals Industry
In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a
These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey
UBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,100
UBS analyst Trung Huynh maintains $Eli Lilly and Co(LLY.US)$ with a buy rating, and adjusts the target price from $910 to $1,100.According to TipRanks data, the analyst has a success rate of 75.5%
Novo's Ozempic Linked to Improved Brain Health: Study
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
On Friday, the European Medicines Agency (EMA) warned patients using weight-loss drugs, such as Novo Nordisk A/S's (NYSE:NVO) Wegovy, to inform their doctors before general anesthesia or deep
Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
Express News | UBS Raises Eli Lilly's Stock PT to $1100 From $910; Shares Last up 1.1%
UBS Raises Price Target on Eli Lilly to $1,100 From $910, Maintains Buy Rating
Eli Lilly (LLY) has an average rating of outperform and price targets ranging from $540 to $1,083, according to analysts by Capital IQ.Price: 938.50, Change: +4.36, Percent Change: +0.47
How to Boost Your Portfolio With Top Medical Stocks Set to Beat Earnings
The EU accuses Eli Lilly and Co (LLY.US) and Novo Nordisk A/S (NVO.US) of having risks of post-anesthetic pulmonary inhalation in weight-loss and blood-sugar-lowering drugs.
European health departments warn that there may be a risk of anesthesia complications for patients who are taking glucose-lowering and weight-loss medications before surgery.
Express News | Eli Lilly and Co : UBS Raises Target Price to $1100 From $910
Express News | EMA's PRAC: Product Information of GLP-1 Ras to Be Updated to Include Warning on Surgery Under Anaesthesia or Deep Sedation
This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment
Eli Lilly and Co(LLY.US) 10% Shareholder Sells US$197.36 Million in Common Stock
$Eli Lilly and Co(LLY.US)$ 10% Shareholder LILLY ENDOWMENT INC sold 210K shares of common stock on Jul 10, 2024 at an average price of $939.816 for a total value of $197.36 million.Source:
Eli Lilly, Novo Nordisk Shares Dip as Pfizer Ramps Up Diabetes Drug Competition
Shares of $Eli Lilly and Co(LLY.US)$ and $Novo-Nordisk A/S(NVO.US)$ finished lower on Thursday, perhaps influenced by competitive developments and regulatory updates in the pharmaceutical sector.